Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation from Natalizumab to Interferon-beta-1b in RRMS
NCT01144052Phase 4Completed
- Sponsor
- Gobbi Novag
- Start
- Jun 2010
- Primary completion
- Nov 2011
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Gobbi Novag. Primary endpoint: Number of Days Until First On-study Relapse at 12 months. Started Jun 2010; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01144052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144052.